Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer;Abschlussbericht über die low-dose estramustinphosphat (EMP) monotherapie und die very low-dose EMP therapie in kombination mit einem LH-RH agonisten für zuvor unbehandelte fortgeschrittene prostatakarzinome

Aktuelle Urologie

Volumn 41, Issue SUPPL. 1, 2010, Pages

  Kitamura, T ^a   Suzuki, M ^a   Nishimatsu, H ^a   Kurosaki, T ^a   Enomoto, Y ^a   Fukuhara, H ^a   Kume, H ^a   Takeuchi, T ^a   Miao, L ^a   Jiangang, H ^a   Xiaoqiang, L ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b Tianjin Inst of Urological Surgery   (China)

Author keywords

Advanced prostate cancer; Estramustine phosphate; Low dose EMP monotherapy; Previously untreated prostate cancer; Very low dose EMP with LH RH agonist

Indexed keywords

ALKYLATING AGENT; ESTRAMUSTINE; GONADORELIN; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CANCER STAGING; CAUSE OF DEATH; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG POTENTIATION; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTRAMUSTINE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 76649088714     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-0029-1224657     Document Type: Article

References (26)

1. Smith D C. Chemotherapy for hormone refractory prostate cancer. Urologic Clinics of North America 1999 26 323-331
2. Perry C M., McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995 7 49-74
3. Olmstead J. Microtubule associated proteins. Ann Rev Cell Biol 1986 2 419-455
4. Van Poppel H, Baert L. The present role of estramustine phosphate in advanced prostate cancer. In: European Organization for Research and Treatment of Cancer. Genitourinary Group Monograph 10 Urological Oncology: Reconstructive Surgery, Organ Conservation, and Restoration of Function. Hoboken, NJ: Wiley-Liss, Inc; 1991: 323-341
5. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol 1997 15 13-19
6. Pienta K J., Fisher E I., Eisenberger M A. et al. A Phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). Prostate 2001 46 257-261
7. Kelly W K., Curley T, Slovin S et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001 19 44-53
8. Petrylak D P., Macarthur R B., O'Connor J et al. Phase1 trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999 17 958-967
9. Kitamura T, Nishimatsu H, Hamamoto T et al. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer. Expert Rev Anticancer Ther 2002 2 59-71
10. Andersson L, Berlin T, Boman J et al. Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study. Scand J Urol Nephrol 1980 55 143-145
11. Benson R CJr, Gill G M. Estramustine phosphate compared with diethylstilbestrol: a randomized, double-blind, crossover trial for stageD prostate cancer. Am J Clin Oncol 1986 9 341-351
12. Hauchecorne J. French multicentre study on the use of estramustine phosphate versus diethylstilbestrol. In: Prostate Cancer, Part B: Imaging Techniques, Radiotherapy, Chemotherapy and Management Issues. Alan R. Liss Inc; 1987: 229234
13. Kuss R, Khoury S, Richard F et al. Estramustine phosphate in the treatment of advanced prostatic cancer. Brit J Urol 1980 52 29-33
14. Smith P H., De Pauw M, Robinson M et al, EORTC Urological Group. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762. Urology 1984 6 (suppl) 64-68
15. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984 311 1281-1286
16. Tyrrell C J., Altwein J E., Klippel F et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue Goserelin Acetate alone and with Flutamide in the treatment of advanced prostate cancer. J Urol 1991 146 1321-1326
17. Gunnarsson P O., Davidsson T, Andersson S-B et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol 1990 38 189-193
18. Kitamura T. Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer. Int J Urol 2001 8 33-36
19. Kitamura T, Nishimatsu H, Suzuki M et al. Dual interim report of low-dose Estramustine Phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer. J Applied Res in Clin Experimet Therapeut 2005 5 331-344
20. Takayasu H, Shida K, Momose S et al. Clinical study on the treatment of prostatic carcinoma with Estracyt. The Nishinihon J Urol 1980 42 715-731
21. Takenaka I, Soramoto S, Kagawa S et al. Multicenter randomized clinical trial comparing estracyt mono-therapy with combined androgen blockade therapy (CAB) in the treatment of advanced prostate cancer. The Nishinihon J Urol 2001 63 1-9
22. Saito S, Nakajima J, Nakajima Y et al. Clinical efficacy of Leuprolide Acetate and combined treatment with Estramustine for advanced prostate cancer. Jpn J Urol 2001 92 682-693
23. Iversen P, Christensen M G., Friis E et al. A phaseIII trial of Zoladex and Flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 1990 66 (5 suppl) 1058-1066 (Pubitemid 20293005)
24. Eisenberger M A., Blumenstein B A., Crawford E D. et al. Bilateral orchiectomy with or without Flutamide for metastatic prostate cancer. NEngl J Med 1998 339 1036-1042
25. Fourcade R O., Cariou G, Coloby P et al. Total androgen blockade with Zoladex plus Flutamide vs. Zoladex alone in advanced prostatic carcinoma: Interim report of a multicenter, double-blind, placebo-controlled study. Eur Urol 1990 18 (suppl3) 45-47
26. Mohammed R, Suzuki M, Takahashi S et al. Incidence of gastrointestinal toxicity during estramustine phosphate therapy for prostate cancer is associated with the single-nucleotide polymorphisms in the cytochrome P450 1A1 (CYP1A1) gene. Cancer Therapy 2005 3 525-530